You are currently visiting the Safic-Alcan Austria website.

Pharmaceuticals

IMATINIB MESYLATE

Provided by Cipla Ltd

About

Human API designed for oncology therapeutic use. It is applicable in tablet dosage form.

Benefits:

  • Meets the requirements of USDMF, EDMF, KDMF and CEP
Category
  • Human API
    • L - Antineoplastic and immunomodulating agents
Chemical NameImatinib mesylate

About cipla ltd

Not Applicable

Let’s build your next solution together

Guiding you through every stage of your innovation journey.

Contact-us